Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Sutent approved for use in U.S. in kidney cancer, gastrointestinal stromal tumors
March 24th, 2006
Sutent, a new cancer drug from Pfizer and developed out of research at the Max Planck Institute of Biochemistry, has been approved by the U.S. Food and Drug Administration (FDA) to treat two kinds of advanced cancers, if standard therapies fail. The cancers are renal cell carcinoma (RCC; kidney cancer) and gastrointestinal stromal tumors (GIST, a rare form of gastrointestinal cancer). Sutent has been developed on the basis of discoveries of Max Planck scientists. Cancer researcher professor Axel Ullrich, a director at the Max Planck Institute of Biochemistry in Martinsried, Germany, already showed at the beginning of the 1990s that blocking blood vessel development in a...
Source: Drug Week (2006-03-24)
|
